These results are consistent with those of previous studies which showed Sorafenib reduces the number and activity of NK cells in HCC tumors by inhibiting ERK phosphorylation and decreasing plasma levels of MCP-1 and IFN-γ [55]. Here, CCL2 is linked to hepatocellular carcinoma.